Free Alerts   Login
Health Care › Biological Products (No Diagnostic Substances)

RGNX Stock Price Correlated With REGENXBIO Financials

RGNX Stock Price vs. Quarterly
RGNX
Income Statement
Cash Flow
Balance Sheet

RGNX Income Statement

Enable JavaScript and reload
Revenue, Net:
Revenue Per Share:
Cost of Goods & Services Sold:
Gross Profit:
Selling, General & Admin Expense:
Research & Development Expense:
Total Operating Expenses:
Operating Income:
Income Taxes:
Net Income:
Earnings Per Share, Diluted:
Earnings Per Share, Basic:
Shares Outstanding, Basic Avg:
Shares Outstanding, Diluted Avg:
Common Stock Shares Outstanding:

RGNX Cash Flow

Enable JavaScript and reload
Operating Activities Net Income:
Depreciation, Depletion & Amortization:
Change in Accounts Receiveable:
Net Cash from Operations:
Net Cash from Operations Per Share:
Repurchases/Buybacks Common Stock:
Issuance of Long-term Debt:
Cash Dividends Paid:
Net Cash from Financing Activities:
Property, Plant & Equipment Purchases:
Purchases of Businesses, Net of Cash:
Net Cash from Investing Activities:
Net Change in Cash & Equivalents:

RGNX Balance Sheet

Enable JavaScript and reload
Cash and Cash Equivalents:
Short-Term Investments:
Accounts Receivable, Net:
Inventories:
Total Current Assets:
Property, Plant & Equipment, Net:
Total Assets:
Accounts Payable:
Current Portion of Long-Term Debt:
Total Short-Term Liabilities:
Long Term Debt, Non-Current Portion:
Total Long-Term Liabilities:
Total Liabilities:

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Blackrock.
8,207,548 sh
181,058 sh
2%
$147,324
$15,208
Vanguard Group
4,440,838 sh
64,265 sh
1%
$79,713
$7,674
JPMorgan Chase
3,939,549 sh
274,185 sh
7%
$70,715
$10,383
Redmile Group
3,760,690 sh
1,186,648 sh
46%
$67,504
$25,135
State Street
2,631,220 sh
127,739 sh
5%
$47,230
$6,023
Morgan Stanley
1,820,382 sh
1,438,467 sh
377%
$32,675
$26,389
Dimensional Fund Advisors
1,226,957 sh
34,385 sh
3%
$22,026
$2,393
Geode Capital Management
929,672 sh
46,526 sh
5%
$16,689
$2,151
Aquilo Capital Management
802,424 sh
-67,690 sh
-8%
$14,404
-$2,990
Jacobs Levy Equity Management
695,184 sh
132,793 sh
24%
$12,479
$3,222
Mpm Oncology Impact Management Lp
549,078 sh
-107,640 sh
-16%
$9,856
-$3,272
Northernrp
446,773 sh
16,738 sh
4%
$8,019
$940
Sonic GP
443,079 sh
250,000 sh
129%
$7,953
$4,302
Ws Management Lllp
431,200 sh
-186,931 sh
-30%
$7,740
-$2,434
Ameriprise Financial
376,728 sh
117,060 sh
45%
$6,762
$2,487
Perceptive Advisors
342,408 sh
342,408 sh
NEW
$6,146
$6,146
Bank Of New York Mellon
337,773 sh
-22,923 sh
-6%
$6,063
$126
Goldman Sachs Group
336,106 sh
-260,748 sh
-44%
$6,033
-$3,791
Charles Schwab Investment Management
327,451 sh
1,683 sh
1%
$5,878
$516
Integral Health Asset Management
325,000 sh
325,000 sh
NEW
$5,834
$5,834

Free historical financial statements for REGENXBIO Inc.. See how revenue, income, cash flow, and balance sheet financials have changed over 32 quarters since 2016. Compare with RGNX stock chart to see long term trends.

Data imported from REGENXBIO Inc. SEC filings. Check original filings before making any investment decision.